In today’s Pharmaceutical Executive Daily, Gilead and Vir Biotechnology enter a collaboration worth up to $1.87 billion to ...
Vir Biotechnology, entered a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN dual-masked T-cell engager development candidates target ...
FDA announced the Rare Disease Framework Initiative, a new effort to reimagine how drugs and biologics for rare diseases are developed and reviewed. The initiative was outlined in ...
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics ...
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona ...
Drug shortages remain a difficult to fix issue for the pharma industry and are an issue that can have devastating results.
Fox Rothschild's Mark Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and ...
If AI is taking over the routine assignments that have traditionally supported an apprenticeship model, through which new ...
Pharmaceutical Executive spoke with Mark Talens, CCO of PAXAFE at LogiPharma 2026 in Boston. During the conversation., the ...
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s ...
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality ...
Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results